Effectiveness of spiramycin for treatment of experimental toxoplasmosis in rats by the Real-time NASBA method

Toxoplasmosis is a main parasitic disease and may cause significant damage to the developing fetus and is a life-threatening opportunistic infection in immunocompromised persons. There are definite drugs available for the treatment of T. gondii infections. These drugs regimen, however, can cause side effects, however the macrolide antibiotic spiramycin is also used as a drug against T. gondii. This study tried to study the effectiveness of spiramycin in the treatment of toxoplasmosis.
The experiments in the present study, fifteen rats received spiramycin 400mg/kg thrice, 15 rats received pyrimethamine-sulfadiazine 150mg/kg once treatment for only one week and 15 rats untreated any drug and were evaluated as the control group. The effectiveness of spiramycin for the treatment of rats experimentally infected with Toxoplasma gondii before and after treated, were analyzed by Real-time NASBA method.
Result of this study showed that spiramycin could be eliminating parasites after 5 days after initiation of treatment in infected rats.
Spiramycin is effectiveness drug in eliminating Toxoplasma gondii in rat's blood and use in pregnant woman.